Generic SupplierYour reliable supplier of generic medications
$0.00 (0 items)Checkout

Categories list

Social bookmarks:

Our billing is certified by:

Secure shopping certificates

Special Offer!

Antivirals

Search by letter:

ABCDEFGHIJKLMNOPQRSTUVWXYZ
 
 
 
Famvir $3.00
Per pill
FamvirFamciclovir 250mg
Buy now!
Lamprene $2.75
Per pill
LampreneClofazimine 50mg
Buy now!
Rebetol $7.50
Per pill
RebetolRibavirin 200mg
Buy now!
Relenza $149.98
Per item
RelenzaZanamivir 5mg
Buy now!
Symmetrel $1.11
Per pill
SymmetrelAmantadine 100mg
Buy now!
Tamiflu $8.00
Per pill
TamifluOseltamivir 75mg
Buy now!
Valtrex $5.22
Per pill
ValtrexValacyclovir 0.5/1g
Buy now!
Zovirax $0.64
Per pill
ZoviraxAcyclovir 200/400/800mg
Buy now!
 
quicksearch
quicksearch

I already received my parcel, I had a problem as the courier wanted to deliver to my home as they claim they cannot place the order into my postbox. This was my preferred option.
There is not someone at home always, so we had to get the parcel to my office. No problem with that.
I did have an enquiry into the 4 extra pills, and this was delivered within a few days via airmail to my post box.
I would suggest you attend to this part of your process as the extra cost is unnecessary. Include everything into one parcel.
All in all, good service. - Jan


Moneyback Guarantee
Subscribe to the News

Latest News

  • Patients' Expectations About New HCV Direct-Acting Antivirals Often Unrealistic - Gastroenterology & Endoscopy News

    Gastroenterology & Endoscopy NewsPatients' Expectations About New HCV Direct-Acting Antivirals Often UnrealisticGastroenterology & Endoscopy Newsby Christina Frangou San Francisco—Soon after the FDA approved two direct-acting antiviral agents (DAAs) last spring for treating infection with hepatitis C virus (HCV), a 57-year-old black man came to see gastroenterologist Andrew Muir, MD.

  • Hepatitis C Study Drug Fails; Most Patients Relapse - Medscape

    Kapitall BlogHepatitis C Study Drug Fails; Most Patients RelapseMedscapeNull responders represent 'a challenging patient population to cure,' said Norbert Bischofberger, PhD, Gilead's chief scientific officer, noting that additional direct-acting antivirals or an extended duration of therapy may be needed to achieve better .

  • Patients relapse after Gilead hepatitis C treatment - PMLiVE

    Patients relapse after Gilead hepatitis C treatmentPMLiVEGS-7977 was one of the main assets behind Gilead's $10.

  • UK company, OnlineClinic, expands services for STI's, travel medicine - Examiner.com

    UK company, OnlineClinic, expands services for STI's, travel medicineExaminer.

  • Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide ... - MarketWatch (press release)

    CitybizlistIdenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide .